Clinical trials: Tranexamic Acid
- Drug or intervention Tranexamic Acid
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Bleeding
Phase II Study to Compare MDCO-2010 vs Placebo and Tranexamic Acid in Patients Undergoing Cardiac Surgery
The objective of this study is to determine the dose response relationship regarding blood loss, PK, PD and clinical outcomes of MDCO-2010 in comparison to placebo and tranexamic acid in patients undergoing primary cardiac…
- Trial name
- NCT01530399
- Testing
- MDCO 1, MDCO 2, MDCO 3
- Where
- 5 sites in Germany, Switzerland
- Volunteers
- 44 people
- Sponsor
- The Medicines Company
Bloodloss, Surgical Procedures, Operative
Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery
A Phase 2 Randomized Double-Blind Active-Controlled Study in Subjects Exposed to Cardio-pulmonary Bypass During Cardiac Surgery at High Risk of Bleeding
- Trial name
- CONSERV-2 (NCT00888940)
- Testing
- Ecallantide, Cyklokapron(R)
- Where
- 34 sites in United States, Germany and 1 more
- Volunteers
- 243 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Menorrhagia, Heavy Menstrual Bleeding
Safety Study of XP12B in Women With Menorrhagia
The purpose of this study is to evaluate the safety of XP12B in women with heavy menstrual bleeding associated with menorrhagia.
- Trial name
- NCT00113568
- Testing
- Tranexamic acid tablets (XP12B)
- Where
- 59 sites in United States
- Volunteers
- 784 people
- Sponsor
- Ferring Pharmaceuticals
Septic Shock
Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148
Septic shock is a potentially life-threatening condition that can result in multi-organ dysfunction syndrome (MODS) and mortality.
- Trial name
- SSAIL (NCT02317549)
- Testing
- LB1148
- Where
- 34 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- Leading BioSciences, Inc
Biliary Tract Surgical Procedures, Pancreaticoduodenectomy
Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Major Abdominal Surgery
Tranexamic acid has been shown to reduce postoperative blood losses and transfusion requirements in various types of major surgery (orthopedic surgery, spine surgery, cardiopulmonary bypass, liver resections, and gynecological…
- Conditions
- Biliary Tract Surgical Procedures, Pancreaticoduodenectomy, Esophagectomy, Colectomy
- Trial name
- NCT00827931
- Testing
- Tranexamic acid + Standard of Care, Standard of Care
- Where
- 2 sites in India
- Volunteers
- 94 people
- Sponsor
- Pfizer
Menorrhagia
A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding
This was a multicenter, open-label extension study for subjects completing either of 2 pivotal efficacy studies (NCT00401193 or NCT00386308).
- Trial name
- NCT01280981
- Testing
- Tranexamic acid
- Where
- 92 sites in United States
- Volunteers
- 288 people
- Sponsor
- Ferring Pharmaceuticals
Menorrhagia
Lysteda Pediatric Research Equity Act (PREA) Pharmacokinetic Study in Adolescent Females With Heavy Menstrual Bleeding
This is a Phase 4, randomized, 2-way crossover, pharmacokinetic study of Lysteda (tranexamic acid) tablets administered as single doses of 0.65 g and 1.3 g in fasting adolescent female subjects ages 12-16 years with heavy…
- Trial name
- PREA (NCT01190150)
- Testing
- tranexamic acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Ferring Pharmaceuticals
Menorrhagia, Heavy Menstrual Bleeding
Efficacy and Safety of XP12B in Women With Menorrhagia
The purpose of this study is to determine whether XP12B is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.
- Trial name
- NCT00401193
- Testing
- Tranexamic acid tablets
- Where
- 83 sites in United States
- Volunteers
- 304 people
- Sponsor
- Ferring Pharmaceuticals
Femoral Fractures
Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Surgery For Long Bone Fracture
Tranexamic acid has been shown to reduce postoperative blood losses and transfusion requirements in a number of types of surgery.
- Trial name
- NCT00824564
- Testing
- Tranexamic Acid plus standard of care, Standard of care
- Where
- India
- Volunteers
- 82 people
- Sponsor
- Pfizer
Spinal Fusion
Efficacy and Safety of Tranexamic Acid in Spinal Fusion Surgery
The purpose of this study is to see if Tranexamic Acid can safely reduce bleeding in people undergoing spinal fusion surgery.
- Trial name
- NCT03425799
- Testing
- Sodium Chloride 0.9% Inj, Tranexamic Acid
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Exela Pharma Sciences, LLC.
Menorrhagia, Heavy Menstrual Bleeding
Efficacy and Safety Study of XP12B in Women With Menorrhagia
The purpose of this study is to determine whether XP12B is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.
- Trial name
- NCT00386308
- Testing
- Tranexamic acid tablets
- Where
- 52 sites in United States
- Volunteers
- 196 people
- Sponsor
- Ferring Pharmaceuticals
Total Knee Arthroplasty
Study of Local Administration of DepoTXA for Reduced Postsurgical Bleeding in Subjects Undergoing TKA
This is a Phase 2, randomized, single-blind, active-controlled dose-ranging study in subjects scheduled to undergo total knee arthroplasty (TKA).
- Trial name
- NCT02922582
- Testing
- DepoTXA, Tranexamic Acid
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Hereditary Angioedema
Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)
Primary Outcome Measures: The primary endpoint was the time to onset of symptom relief of the first attack in the double blind phase.
- Trial name
- FAST2 (NCT00500656)
- Testing
- Icatibant, Tranexamic Acid
- Where
- Italy
- Volunteers
- 85 people
- Sponsor
- Shire